# Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer

Source: https://onco.cc/key-papers/paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016/  
OnCo record `paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Combining a BRAF inhibitor with a MEK inhibitor shrank tumours in about two thirds of previously treated patients with BRAF V600E-mutant lung cancer, far more than BRAF inhibition alone, leading to the first approval for this driver.

## Summary

Phase 2 multicohort study; this cohort treated 57 patients with previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer with dabrafenib plus trametinib.

Objective response was 63.2 percent with a median progression-free survival of 9.7 months, compared with 33 percent for dabrafenib alone in an earlier cohort; pyrexia, nausea and fatigue were common.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: The Lancet Oncology
- Year: 2016
- DOI: 10.1016/S1470-2045(16)30146-2
- Authors: Planchard D, Besse B, Groen HJM, et al.
- Findings: Objective response 63.2 percent.; Median progression-free survival 9.7 months.
- What it means: BRAF V600E is a routinely tested lung cancer driver, and BRAF plus MEK inhibition is the standard targeted therapy for it.
- Caveats: Single-arm study with 57 patients.; Non-V600 BRAF mutations do not respond.

## Sources

- Lancet Oncol 2016: https://doi.org/10.1016/S1470-2045(16)30146-2
- PubMed: https://pubmed.ncbi.nlm.nih.gov/27283860/

## Connected records

- cancers: [BRAF V600E-mutant non-small-cell lung cancer](https://onco.cc/cancers/braf-v600e-nsclc/)
- drugs: [Dabrafenib](https://onco.cc/drugs/dabrafenib/), [Trametinib](https://onco.cc/drugs/trametinib/)
- journals: [The Lancet Oncology](https://onco.cc/journals/lancet-oncology/)

---
JSON: https://onco.cc/api/v1/entities/paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016.json